← All stories
Markets
STAT+: FDA approves Replimune melanoma drug previously rejected twice
2 outlets - including Biopharmadive and Statnews - are covering this story. The accelerated clearance follows two earlier rejections and the support of an advisory panel that disputed the arguments of FDA scientists.
Covered by 2 outlets
All coverage · 2 articles
BioPharma Dive
·Aug 6, 21:00 UTC
Replimune rebounds to win FDA approval of melanoma drug
The accelerated clearance follows two earlier rejections and the support of an advisory panel that disputed the arguments of FDA scientists.
STAT News
·Aug 6, 19:59 UTC
STAT+: FDA approves Replimune melanoma drug previously rejected twice
The FDA approved Replimune’s treatment for advanced melanoma, dealing the company and patient advocates a big win after a tumultuous saga.